Prospective monitoring of immune signatures in newly diagnosed high risk multiple myeloma patients under treatment with Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (I-KRd): First results of the GMMG-CONCEPT trial
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2019）
关键词
High risk,immunophenotype,isatuximab
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要